Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

105.55 -0.69 (-0.65%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

24 25 Next >

Incyte to Report Second Quarter Financial Results

July 11, 2023

From Incyte

Via Business Wire

2 Low-Priced Stocks That Could Make You Richer ↗

June 26, 2023

These two low-priced healthcare stocks could skyrocket within the next 12 months.

Via The Motley Fool

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

May 25, 2023

From Incyte

Via Business Wire

Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales ↗

May 02, 2023

Incyte's biggest moneymaker, Jakafi, missed first-quarter forecasts.

Via Investor's Business Daily

Why Incyte Shares Are Falling Today ↗

May 02, 2023

Incyte Corporation's (NASDAQ: INCY) shares are plunging today after the

Via Benzinga

Earnings Outlook For Incyte ↗

May 01, 2023

Via Benzinga

Incyte to Present at Upcoming Investor Conferences

May 23, 2023

From Incyte

Via Business Wire

Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

May 08, 2023

From Incyte

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗

May 04, 2023

Via Benzinga

Ominous Death Cross Forms On Incyte's Chart ↗

April 13, 2023

Via Benzinga

What 13 Analyst Ratings Have To Say About Incyte ↗

March 28, 2023

Via Benzinga

Incyte Stock Dives On Surprise Rejection For Updated Jakafi ↗

March 24, 2023

The company had hoped to gain approval for an extended-release version of its biggest drug.

Via Investor's Business Daily

Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review ↗

May 05, 2023

The major indexes retreated for most of the week on banking fears,

Via Investor's Business Daily

Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 02, 2023

From Incyte

Via Business Wire

Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

May 01, 2023

From Incyte

Via Business Wire

What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks ↗

April 21, 2023

Incyte Corporation (NASDAQ: INCY) will report Q1 FY23 results on May 2. Investor focus remains on the Opzelura launch, which has faced some hiccups over the first 18 months of launch and began to gain...

Via Benzinga

Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

April 20, 2023

From Incyte

Via Business Wire

7 Biotech Stocks That Could Cure Your Portfolio Woes ↗

April 19, 2023

If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.

Via InvestorPlace

Incyte to Present at Upcoming Investor Conferences

April 18, 2023

From Incyte

Via Business Wire

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

April 16, 2023

From Incyte and MorphoSys U.S. Inc.

Via Business Wire

The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech ↗

April 14, 2023

One executive called this the most "damaging" decision in five decades.

Via Investor's Business Daily

Incyte to Report First Quarter Financial Results

April 11, 2023

From Incyte

Via Business Wire

S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday ↗

April 10, 2023

Micron and Charles Schwab were among the top performers.

Via Investor's Business Daily

Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target ↗

April 10, 2023

Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023 ↗

April 10, 2023

Via Benzinga

Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday ↗

April 10, 2023

Credit Suisse boosted the price target for The Boeing Company (NYSE: BA) from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to...

Via Benzinga

Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)

March 27, 2023

From Incyte

Via Business Wire

Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact' ↗

March 24, 2023

Via Benzinga

Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets

March 23, 2023

From Incyte

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Incyte Corporation - Common Stock (NQ:INCY)

All News about Incyte Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today